Vir Biotechnology (VIR) Q3 2026 earnings review
Vir Biotechnology signs Gilead deal, but FDA slows second drug
Vir Biotechnology, a developer of immune therapies for liver disease and cancer, brought in another major partner while waiting for its first late-stage trial results. The company signed a preclinical cancer deal with Gilead worth $90 million upfront and kept its first Phase 3 hepatitis delta readout on track for this quarter. Chief executive Marianne De Backer also said its lead prostate cancer drug cleared the bar to start final-stage trials next year, while quarterly cash use of $107 million matched the pace required by its funding plan.
| Cash and investments | $901.3M -$106.5M from last quarter (excludes $90M from Gilead) |
|---|---|
| Research and development expense | $80.0M +4.7% from a year ago excluding last year's $75M one-off |
| Net loss per share | $0.57 $1.17 loss a year ago |
| Cash funding outlook | Unchanged funds operations into the second half of 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because the drugmaker filled its empty chief financial officer and chief medical officer seats and brought in $90 million from Gilead without giving up rights to its clinical-stage drugs. One caution: regulators asked for extra dosing groups on its second cancer drug, VIR-5818, pushing a planned 2026 data readout to an unnamed future conference.
The question now is whether the two-drug hepatitis delta treatment can clear the virus in Phase 3 trials and justify building a US sales force. One view is that strong virus clearance will drive doctors to test and switch patients quickly; the other is that low US diagnosis rates and an approved rival will cap sales while cash runs down. This quarter's ECLIPSE 1 trial readout will provide the first answer.
🐂 Bull Case
Gilead Deal Adds $90 Million for Preclinical Cancer Drugs
Vir relies on large pharmaceutical partners to help pay for its drug research. In the third quarter, the biotechnology company signed an agreement with Gilead "to discover and engineer three novel PRO-XTEN ® dual-masked T-cell engager development candidates" that attack solid tumors. PRO-XTEN is a chemical shield that keeps cancer drugs inactive until they reach a tumor, protecting healthy tissue.
- Upfront cash and stock: $90 million total, comprising $65 million in cash and $25 million in stock sold at a 30% premium
- Near-term research targets: up to $45 million in payments before human trials begin
- Long-term payouts: up to $1.74 billion in later clinical, regulatory and sales payments, plus tiered royalties
This third partnership since December brings total cash raised from deals and stock sales past $600 million. Because these three cancer targets have not yet entered human testing, the US group collects $90 million without giving up rights to its clinical-stage drugs.
What to watch: the virtual research investor event in the first quarter of 2027. Naming the new preclinical cancer targets there will show whether Vir keeps enough wholly owned drugs after licensing three to Gilead.
Lead Prostate Cancer Drug Clears Bar for Late-Stage Trials
"We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology," chief executive Marianne De Backer said. In cancer, the company's lead drug is VIR-5500, an immune therapy developed with Astellas for advanced prostate cancer.
During the quarter, VIR-5500 received Fast Track status from US regulators and met its internal proof-of-concept goal, "reinforcing the scientific rationale for advancing the program into late-stage development". The partners now plan to start multiple final-stage trials in 2027 across six patient groups. Meanwhile, the company will present Phase 2 liver disease data at a medical meeting on November 8 and still expects first results from ECLIPSE 1, its first Phase 3 trial in chronic hepatitis delta, before year-end.
What to watch: the start of the first Phase 3 prostate cancer trial in 2027. Opening that study will trigger development payments from Astellas and prove the six Phase 1 test groups produced clear dosing rules.
New Finance and Medical Chiefs Fill Empty Leadership Seats
Four senior leaders and board members left the drugmaker between April and July 2026, leaving the chief financial officer and chief medical officer seats empty right before major clinical readouts. On the last quarterly call, De Backer said interviews were underway to fill both jobs.
This quarter, the San Francisco company hired Aziz Sawaf as chief financial officer and David Liu as chief medical officer, and added Suzanne Topalian to its board of directors. Filling both executive seats removes the risk of steering Phase 3 liver disease filings and cancer trial designs under temporary managers.
What to watch: the first-quarter 2027 oncology investor event. How Liu sets the clinical rules for the next wave of cancer drugs will show if the new medical leadership is changing the research plan.
🐻 Bear Case
FDA Feedback Pushes Back Second Cancer Drug Timeline
VIR-5818 is the drugmaker's second masked immune therapy, built to attack solid tumors that carry the HER2 protein. For the past three quarters, the company told investors to expect updated Phase 1 response results in the second half of 2026.
That 2026 readout is off the calendar. Following recent feedback from the US Food and Drug Administration under Project Optimus, an agency push to verify cancer drug doses early, Vir will "add backfill cohorts in a more homogeneous patient population in the monotherapy arm of the study to determine optimal dose and schedule". It now plans to share data only "at a future scientific conference".
While De Backer claims broad momentum in cancer, this delay leaves the entire PRO-XTEN platform relying on a single clinical drug, VIR-5500, to prove the technology works in patients.
What to watch: the 2027 conference schedule for VIR-5818. A readout that still lacks a chosen dose or tumor type would signal that the drug cannot find a safe, effective window.
Cash Burn Leaves Little Room for a Solo Drug Launch
The company ended September with $901.3 million in cash and investments, down $106.5 million over the three months. That figure excludes the $90 million from Gilead, which arrived after the quarter closed and lifts the pro forma balance to about $991 million by our math.
Even with the extra $90 million, management kept its cash outlook unchanged, stating the balance will fund operations "into the second half of 2028". By our math, spending $991 million over the nine quarters to the end of 2028 equals $110 million a quarter, right in line with this quarter's $106.5 million outflow. That leaves little room to hire a US sales force for its liver disease drug without raising more money.
What to watch: fourth-quarter cash and investments, after adding the $90 million Gilead payment. A year-end balance below $880 million would mean quarterly spending has climbed above $110 million before commercial hiring even starts.
Risks this quarter didn't answer
Five standing concerns around clinical readouts, commercial adoption and expense tracking got no new data in the third-quarter release.
- Make-or-break ECLIPSE 1 readout: the first Phase 3 hepatitis delta result arrives in the fourth quarter of 2026, and a weak reading would stall the lead program.
- Low US diagnosis rates: only 10% to 15% of US hepatitis delta patients are diagnosed; November's liver conference guidelines will show if testing rules expand.
- Incumbent liver drug competition: an approved rival is already signing up patients ahead of the first-quarter 2027 ECLIPSE 2 and 3 switch and head-to-head readouts.
- EGFR cancer drug class risk: a rival dropped a similar masked drug, and Phase 1 data from VIR-5525 is needed to prove Vir's version avoids the same toxicity.
- Missing per-program costs: the release gives only a single $80.0 million research figure, hiding how much Astellas and Norgine reimbursements cut each program's bill.
💲 Other KPIs
Research spending fell 47.2% from a year ago on paper, but last year included a one-time $75.0 million payment for starting human trials of VIR-5525. Excluding that one-off by our math, underlying research costs rose 4.7% from a year ago as higher manufacturing bills outweighed cost-sharing payments from partners Astellas and Norgine.
Overhead and legal spending rose 9.9% from $22.2 million a year ago due to higher advisory and legal fees. However, costs dropped 19.1% from $30.2 million in the second quarter, when the biopharmaceutical group paid closing fees on the Astellas partnership. Non-cash stock compensation made up $6.0 million of the quarter's bill.
The average share count jumped 21.8% from 138.9 million a year ago because the drugmaker sold stock in a February public offering and issued shares to Astellas in the second quarter. From June to September, total shares issued barely moved, rising 0.1% to 169.4 million before the new Gilead stock purchase closed.
🔮 Guidance
Unchanged. The plan still has current cash and investments paying for operations into the second half of 2028. By our math, stretching $901.3 million across the eight to nine quarters through late 2028 allows $100 million to $113 million of spending per quarter, or up to $124 million including the $90 million Gilead payment. Management previously extended this horizon twice, from mid-2027 to mid-2028 and then to late 2028.
❓ Key Questions
Why didn't the $90 million Gilead payment extend the cash horizon?
Collecting $90 million equals almost a full quarter of cash spending, yet the company kept its funding outlook at the second half of 2028. Investors need to know if 2027 Phase 3 prostate cancer trials or liver launch preparations increased planned spending.
How many patients and months will the VIR-5818 dose cohorts add?
Adding new patient groups to satisfy FDA dosing rules pushed the VIR-5818 readout out of 2026. Knowing the size of the cohorts and the target conference date will show whether the program is delayed by months or a full year.
How much did Astellas and Norgine reimbursements lower research spending?
Research costs dropped to $80.0 million partly because partners shared clinical bills, but the release gives no dollar figure for those recoveries. Without the exact reimbursement, investors cannot calculate the true quarterly cost of running the trials.
Which three cancer targets did Gilead license from the preclinical pipeline?
Vir previously highlighted seven preclinical masked cancer programs and has now licensed three to Gilead. Clarifying whether Gilead took the most advanced candidates will show what remains for Vir to develop on its own at the first-quarter 2027 investor event.